Novo Nordisk Pharmaceuticals, Inc.

Novo Nordisk Pharmaceuticals, Inc. in Princeton, N.J. is a United States affiliate of Novo Nordisk A/S, a healthcare company and a world leader in diabetes care. Novo Nordisk works with healthcare providers, research organizations, and patient associations to enhance knowledge about diabetes and the best therapies available. Novo Nordisk uses recombinant technology to make a comprehensive line of human insulin and insulin analog products and an oral antidiabetic agent. Novo Nordisk designed and developed the world’s first insulin pen device and today is a leader in the production of innovative insulin delivery systems. To learn more, please visit a Novo Nordisk Pharmaceutical Sales Representative at the Novo Nordisk booth in the Health Fair.

Victoza (liraglutide) for Type 2 Diabetes: the Once Daily GLP-1 Incretin Mimetic In January of 2010, the Food and Drug Administration (FDA) approved the use of Victoza (liraglutide) in the United States in adults with type 2 diabetes in order to improve glycemic control in addition to diet and exercise. Now, Victoza joins Byetta (exenatide) in the class of drugs called GLP-1s.

Incretin Mimetics Steven V. Edelman, MD TCOYD Newsletter, Vol. 25, 2008 Developments in an Important Class of Treatments for Type 2 Diabetes Diabetes affects multiple hormones in the body; not just insulin. Incretins are hormones released from the intestines after eating that cause insulin secretion and appetite suppression.